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Abstract
We evaluated factors associated with improvement in neurocognitive performance in 258 HIV-
infected adults with baseline CD4 lymphocyte counts above 350 cells/mm3 randomized to
intermittent, CD4-guided antiretroviral therapy (ART) (128 participants) versus continuous
therapy (130) in the Neurology substudy of the Strategies for Management of Antiretroviral
Therapy trial. Participants were enrolled in Australia, North America, Brazil, and Thailand, and
neurocognitive performance was assessed by a five-test battery at baseline and month 6. The
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primary outcome was change in the quantitative neurocognitive performance z score (QNPZ-5),
the average of the z scores of the five tests. Associations of the 6-month change in test scores with
ART use, CD4 cell counts, HIV RNA levels, and other factors were determined using multiple
regression models. At baseline, median age was 40 years, median CD4 cell count was 513 cells/
mm3, 88 % had plasma HIV RNA ≤400 copies/mL, and mean QNPZ-5 was −0.68.
Neurocognitive performance improved in both treatment groups by 6 months; QNPZ-5 scores
increased by 0.20 and 0.13 in the intermittent and continuous ART groups, respectively (both
P<0.001 for increase and P=0.26 for difference). ART was used on average for 3.6 and 5.9 out of
the 6 months in the intermittent and continuous ART groups, respectively, but the increase in
neurocognitive test scores could not be explained by ART use, changes in CD4, or plasma HIV
RNA, which suggests a practice effect. The impact of a practice effect after 6 months emphasizes
the need for a control group in HIV studies that measure intervention effects using neurocognitive
tests similar to ours.
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Introduction
Untreated HIV infection may impair neurocognitive function (McArthur et al. 2010; Price et
al. 1988). With the introduction of combination antiretroviral therapy (cART), the incidence
of HIV-associated dementia declined sharply (Bhaskaran et al. 2008; d’Arminio Monforte et
al. 2004; Dore et al. 1999; Lescure et al. 2011; McArthur 2004; McArthur et al. 2010;
Sacktor et al. 2001). Nevertheless, recent studies suggest that the prevalence of
neurocognitive disorders remains substantial even among individuals with high CD4
lymphocyte cell counts and suppressed viral load (Cysique and Brew 2011; Heaton et al.
2010; McArthur et al. 2010) and that up to 52 % of HIV-infected individuals exhibit some
form of neurocognitive impairment (NCI). The reasons for that are uncertain but may
include confounding factors, a legacy effect of irreversible injury before therapy was
initiated, ongoing indolent injury, and perhaps neurotoxic effects of antiretroviral therapy
(ART) (Al-Khindi et al. 2011; Heaton et al. 2011; Robertson et al. 2010). While many
longitudinal studies have reported improvements in neuropsychological test scores after
starting cART (Al-Khindi et al. 2011), few HIV studies have investigated the test–retest
practice effect as a possible explanation.
The Strategies for Management of Antiretroviral Therapy (SMART) study randomized HIV-
infected adults with CD4 cell counts above 350 cells/mm3 to intermittent, CD4-guided
ARTor continuous ART (El-Sadr et al. 2006). In a Neurology substudy, a neurocognitive
test battery was administered (Wright et al. 2010), in order to compare intermittent to
continuous ART for changes in neurocognitive performance. We hypothesized that
neurocognitive performance would be superior in participants receiving continuous ART
because of the sustained reduction in HIV replication. The intermittent ART arm in the
parent SMART study was stopped early, however, due to a higher incidence of progression
of disease and death, and continuous ART was recommended to all participants; at that time,
only 292 of the planned 600 Neurology substudy participants were enrolled. Consequently,
the substudy was underpowered for the planned primary comparison. Surprisingly, though,
neurocognitive performance had increased significantly in both study arms. The main goal
of the current analysis was to examine the basis of this finding, including whether the
improvement in neurocognitive test scores could be explained as a benefit of ART.
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The SMART study was an international randomized trial comparing continuous ARTwith
CD4 cell count-guided, intermittent ART in HIV-infected adults with CD4 cell counts above
350 cells/mm3. The study design is described elsewhere (El-Sadr et al. 2006). Participants in
the intermittent ART arm stopped or deferred ART until the CD4 cell count declined to
below 250 cells/mm3 and, thereafter, used ART with the goal of viral suppression until the
CD4 count had recovered to above 350 cells/mm3. The primary outcome of the
neurocognitive component of the SMART Neurology substudy was a quantitative
neurocognitive performance z score (QNPZ-5), based on a five-test neurocognitive test
battery. The study was designed to enroll 600 participants, follow them up for 5 years, and
administer the test battery at baseline, month 6, and annually thereafter. The Neurology
substudy commenced enrollment in July 2005. In January 2006, enrollment and the
intermittent CD4-guided ART strategy of the SMART study were stopped due to increased
risk of AIDS and serious non-AIDS complications, and participants were recommended to
restart ART (El-Sadr et al. 2006). At the time of this protocol change, only 292 of the 600
planned substudy participants were enrolled. Data collection in this substudy continued until
July 2006, when all participants had been followed up for 6 months.
Participants were enrolled at 47 sites in Australia, North America, Brazil, and Thailand. At
these sites, all eligible SMART participants were offered substudy co-enrollment. Substudy
eligibility criteria included age ≥18 years and the ability to perform the study’s
neurocognitive tests in the site clinician’s judgment.
Standard protocol approvals, registrations, and patient consents
Substudy approval was obtained by each site’s institutional review board; the study is in
accordance with the Helsinki Declaration of 1975, as revised in 2000. All participants
provided written informed consent. ClinicalTrials.gov identifier: NCT00432003.
Outcome measures
The five-test neurocognitive test battery comprised the Grooved Pegboard (GPB) (dominant
hand) (Klove 1963), Color Trails 1 and 2 (CT1 and CT2) (D’Elia et al. 1996), Timed Gait
(TG) (Robertson et al. 2006), and Finger Tapping (FT) (nondominant hand) (Reitan 1969)
tests, described previously (Wright et al. 2010). The tests closely resemble the battery used
in a large, randomized HIV treatment study (Price et al. 1999).
For the individual tests, the raw scores of each participant were standardized to z scores
(Wright et al. 2010). A negative z score denotes below-average performance relative to an
HIV-negative US reference population, and a z score of −1 corresponds to performance at 1
standard deviation below the average of the reference population. Reference distributions
were provided by the licensors of the tests (GPB, CT, and FT) or obtained from published
studies (TG), matched by education level for all five tests, and, where available, additionally
by age (GPB, CT, and FT), sex, and race/ethnicity (GPB and FT) (Heaton et al. 2004; Morey
2006; Reitan 1969; Robertson et al. 2006).
The primary neurocognitive performance outcome measure, the QNPZ-5, was calculated as
the average of the five z scores from the five individual tests in the battery. To further
describe the study population, we defined NCI as z scores<−2 in at least two ability
domains. Ability domains assessed were (1) speed/fine motor skills (GPB and FT), (2)
attention/speed of processing (CT1), (3) executive function (CT2), and (4) gross motor skills
(TG). The cutoff was chosen to reflect the Frascati criteria for abnormal neurocognitive
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performance, although the test battery was too small to meet the formal Frascati criteria;
also, we did not assess whether individual low test scores might be explained by
comorbidities (Antinori et al. 2007).
Neuropsychological tests were administered to participants by site staff, including medical
practitioners, specialists, and nurses. Site staff underwent centralized training and
certification in the USA and Australia, as previously described (Wright et al. 2010).
Training was led by a neuropsychologist or neurologist and an infectious disease physician.
Demography, HIV history, general medical history, ART use, and laboratory values were
collected within the parent SMART study. Adherence to ART was collected by patient self-
report, using a 7-day recall questionnaire at baseline and month 4; participants who took at
least 80 % of their medication were considered adherent for the current analysis. The central
nervous system (CNS) penetration effectiveness (CPE) rank of patients’ ART regimens was
calculated using the 2010 revision of the CPE score (Letendre et al. 2010).
Statistical methods
Mean baseline neuropsychological test scores (the QNPZ-5 and individual test z scores)
were compared to 0 using two-sided t tests; values below 0 denote below-average test
performance compared to an HIV-negative reference population. Treatment groups were
compared for month 6 changes in test scores by intent-to-treat, using unadjusted t tests, as
well as using ANCOVA adjusted for change in CD4 cell counts and HIV RNA levels. Mean
changes in test scores, overall and in various subgroups, were compared to 0 using t tests.
Homogeneity across the locations of enrollment was assessed using analysis of variance
(ANOVA; baseline z scores, changes in z scores). For six participants, one out of the five
individual test scores was missing, and change in QNPZ-5 was calculated as the average of
change in the individual z scores for the four available tests.
In order to determine whether the increases in QNPZ-5 and individual test z scores could be
explained by changes in CD4 cell counts, plasma HIV RNA, or ART use, the associations of
these factors with changes in test scores were calculated using univariate and multiple linear
regression and Spearman’s correlation coefficient. Subgroups by ART status at baseline and
month 6 were compared for changes in QNPZ-5 by ANOVA and using t tests for contrasts
with and without Scheffé’s adjustment for multiple comparisons (to adjust for post hoc
analyses).
In multiple linear regression models for change in neurocognitive test z scores, we always
included demographics (age, years of education, sex, and location of enrollment) to account
for imperfect standardization of test scores using US reference populations, as well as the
baseline test scores, because of a possible association of baseline with change in test scores
due to regression to the mean. In a first model, we also included change in CD4 cell counts
and log10 HIV RNA because the beneficial effects of ART would likely be mediated
through these factors. We did not include race/ethnicity because it was strongly confounded
with the location of enrollment. Coefficients were presented when the P value for
association was at least 0.10. The analysis was repeated within each treatment group. In
further models, all adjusted for demographics and baseline test scores, we investigated
associations with single baseline factors, for example, duration and CPE rank of ART.
Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA) and R
version 2.10 (R Development Core Team 2011). All tests were two-sided. P values≤0.05
were considered significant.
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Study population and baseline characteristics
The analysis includes all 258 participants in the Neurology substudy with both baseline and
month 6 neurocognitive test data (Australia/USA, 98; Brazil, 17; Thailand, 143). Of these,
128 were randomized to intermittent ART and 130 to continuous ART (Fig. 1). Baseline
characteristics and neurocognitive test scores are summarized in Tables 1 and 2; the
treatment groups were well balanced for baseline characteristics. Median CD4 cell count
was 513 cells/mm3, median nadir CD4 count was 216 cells/mm3, and 88 % had plasma HIV
RNA≤400 copies/mL. Only 4 % of participants were ART-naïve; 93 % were using ART at
baseline, with a median of 4 years of prior ART use. ART regimens had a median CPE rank
of 7, on a scale of 1–4 for each drug (Table 1).
Overall, the mean QNPZ-5 score was −0.68 (P<0.001 for comparison to 0), denoting below-
average performance compared to a healthy reference population. For four of the five
individual tests, the average z score was negative (P<0.05 for each; Table 2). Fourteen
percent of participants met the study definition of NCI (z scores<−2 in two or more ability
domains); 52 % had z scores<−1 in two or more cognitive domains.
Mean QNPZ-5 scores differed by location of enrollment (−0.77 in Australia/USA, −0.15 in
Brazil, and −0.68 in Thailand; P=0.01 for comparison between locations). No one region
performed consistently higher or lower across all tests. Baseline characteristics and test
scores by location of enrollment are described elsewhere (Wright et al. 2010).
Change in neurocognitive performance
Changes in the QNPZ-5 and in individual test z scores from baseline to month 6 are
summarized in Table 2 and, by treatment group, in Fig. 2a. QNPZ-5 scores increased by
0.20 in the intermittent ART group (95 % CI, 0.12 to 0.29; P<0.001 for increase) and by
0.13 in the continuous ART group (95 % CI, 0.03 to 0.23; P=0.009). The estimated mean
change in z scores was positive for each of the five tests in both treatment groups, and the
increase was significant for GPB, CT1, and CT2 (P<0.001 each; Table 2 and Fig. 2). The
increases in QNPZ-5 and z scores were homogeneous across locations (all P>0.20).
There was no evidence for a difference between the intermittent and continuous ART groups
in either mean change in QNPZ-5 (estimated difference, 0.07; 95 % CI, −0.06 to 0.20;
P=0.26) or in any of the individual test z scores (all P>0.10). Moreover, the direction of the
treatment difference was inconsistent across the tests (Fig. 2a).
ART use
Participants in the intermittent ART group stopped or deferred ART at randomization, but
108 (86 %) had restarted ART by 6 months. Of those, 86 (80 %) restarted ART after January
11, 2006, when participants were recommended to resume ART. ART use is summarized in
Fig. 1. Participants in the intermittent ART group used ART for an average of 3.6 of the 6
months, compared with 5.9 months in the continuous ART group. Adherence was excellent;
among those who were receiving ART at month 4, 100 % in the intermittent ART arm and
98 % in the continuous ART arm self-reported adhering to their regimen; at month 6,
adherence was not assessed, but among those receiving ART, 90 and 93 %, respectively, had
HIV RNA≤400 copies/mL.
Factors associated with change in neurocognitive performance
In order to investigate whether initiation of ART could explain the increase in QNPZ-5
scores, we evaluated the mean change in QNPZ-5 scores within subgroups by ART status at
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baseline and at month 6. The four groups are described in Fig. 1, and mean change in
QNPZ-5 scores is shown in Fig. 2b. Differences between the four groups were not
statistically significant by ANOVA (P=0.07). However, when comparing participants
according to their ART status at month 6, those who continued or started ART (groups 1 and
3 pooled in Fig. 2b) improved less than those who stopped or never started ART (groups 2
and 4 pooled) (estimated mean difference, −0.36; P=0.01 unadjusted, P=0.11 after Scheffé’s
adjustment for multiple comparisons). The duration of ART use during the 6 months was not
associated with change in QNPZ-5 (Spearman’s r=−0.07, P=0.25). Similarly, the change in
the CPE rank of ART was not associated with change in QNPZ-5 among the 224
participants who were using ART at both baseline and month 6 (mean change in CPE rank,
−0.1; Spearman’s r=0.08, P=0.22); mean CPE ranks in each ART group are shown in Fig.
2b.
Table 3 summarizes the associations of baseline factors, change in CD4 cell counts, and
change in plasma HIV RNA with changes in QNPZ-5 and individual test z scores, estimated
in multiple regression models. Lower baseline QNPZ-5 was associated with steeper
increases in QNPZ-5 from baseline to month 6 (0.23 units higher per 1 unit baseline
QNPZ-5 lower); similar associations held for each individual test z score (all P<0.001; Table
3). Mean increases in QNPZ-5 were by 0.14 lower for women compared with men.
Overall changes in plasma HIV RNA levels were small, as most participants were using
ARTat baseline and continued or had restarted ART by month 6; mean log10 HIV RNA
levels increased by 0.1 log10 copies/mL in the intermittent ART group and decreased by 0.1
log10 copies/mL in the continuous ART group. A tenfold increase in HIV RNA (1 log10
copies/mL) was independently associated with a 0.15 higher than average increase in
QNPZ-5 (Table 3); this association was similar in both treatment groups (data not shown).
By month 6, mean CD4 cell counts had decreased by 21 cells/mm3 in the intermittent ART
group and increased by 33 cells/mm3 in the continuous ART group. In the intermittent ART
group, a 6-month increase in CD4 cell count was associated with a slightly steeper increase
in QNPZ-5, by 0.03 per 50 cells/mm3 CD4 increase (P=0.05). There was no evidence for an
association within the continuous ART group or in the pooled analysis of both treatment
groups (Table 3).
After adjustment for change in CD4 cell counts and log10 HIV RNA, the estimated mean
increase in QNPZ-5 scores remained significant within each group, almost unchanged at
0.20 for the intermittent ART group, and 0.15 for the continuous ART group (Fig. 2a).
There was no evidence that experiencing a grade 4 or AIDS event was associated with a
change in QNPZ-5; seven participants had experienced such an event by month 6. We also
investigated the associations of change in QNPZ-5 in a multiple regression model that
contained only baseline factors. Coefficients and P values for baseline QNPZ-5, age, sex,
and location of enrollment were similar to those shown in Table 3. Higher baseline CD4 was
independently associated with less increase in QNPZ-5 (−0.04 less than the average increase
per 100 cells/mm3 higher; P=0.02), but there was no independent association with ART use
at study entry or the duration of prior ART use.
Discussion
In this prospective study of 258 participants from Australia, North America, Brazil, and
Thailand with CD4 cell counts>350 cells/mm3, we found that neurocognitive performance,
measured by mean change in QNPZ-5 scores, increased by month 6 among participants
receiving intermittent ART as well as among those receiving continuous ART. The increase
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in QNPZ-5 scores in both treatment groups suggests a practice effect. The presence of a
practice effect emphasizes the importance of including a control group in studies that use
test batteries like ours to evaluate the effect of an intervention.
We have investigated and excluded ART use as a possible explanation for the increase in
QNPZ-5 in both arms:
1. The increase in QNPZ-5 scores could not be explained as a beneficial effect of
ART use mediated through the suppression of plasma HIV RNA or increase in
CD4 cell counts. On the contrary, an increase in viral load was associated with
higher than average improvements in QNPZ-5 scores (Table 3), and change in CD4
was not independently associated with change in QNPZ-5.
2. In our cohort, there is no indication that starting or continuing ART contributed to
the increase in QNPZ-5 in other ways. In fact, among the 16 participants who were
not using ART at baseline and started ART, the average QNPZ-5 declined,
compared with increases for all other participants (Fig. 2b). Duration of ART use
during the 6-month follow-up in the study was not associated with changes in
QNPZ-5 (Spearman’s r=−0.07, P=0.25), nor was prior ART use, or changes in the
CPE rank of ART among those who were using ART at study entry and remained
on ART throughout follow-up (r=0.08, P=0.22). Moreover, increases in mean
QNPZ-5 scores were largest for participants who never started ART or had stopped
ART by month 6 (groups 2 and 4 in Fig. 2b).
The presence of a practice effect when neuropsychological tests are repeated after 6–12
months is well documented in the general population (Heilbronner et al. 2010; McCaffrey et
al. 2000). The American Academy of Clinical Neuropsychology advises that “the primary
element requiring careful consideration in serial testing is the practice effect … A change in
scores on repeat testing can lead to … attributing improved scores to recovery of function or
efficacy of intervention when the results are more likely to reflect the effects of test
practice” (Heilbronner et al. 2010). Nevertheless, in HIV research, the practice effect has
often been neglected when evaluating interventions. For example, in a recent meta-analysis
of 23 longitudinal studies investigating the effect of ART on neurocognitive function (Al-
Khindi et al. 2011), 11 assessed the effect of ART by comparing test scores before and after
cART initiation. All 11 studies reported improvement in test scores after 3–6 months
(Brouwers et al. 1997; Carvalhal et al. 2006; Chang et al. 2003; Robertson et al. 2004;
Sacktor et al. 2006, 2009; Tozzi et al. 1993, 1999, 2001, 2009; Winston et al. 2010). Of the
11 studies, only 6 even mentioned the possibility of a practice effect (Brouwers et al. 1997;
Chang et al. 2003; Robertson et al. 2004; Sacktor et al. 2006, 2009; Tozzi et al. 1993). Only
two of the studies formally adjusted for practice effect; in both studies, little evidence
remained for a benefit of ART on neurocognitive performance after the adjustment (Chang
et al. 2003; Sacktor et al. 2009).
In our cohort, increases in viral load were associated with higher-than-average increases in
QNPZ-5 scores. This finding is contrary to the expectation that suppressing viral load is
protecting the brain and, therefore, should lead to an improvement in neurocognitive
performance (Marcotte et al. 2003; Wright 2011). It is contrary also to a small, single-arm
prospective study of treatment interruption (n=11), where the global deficit score remained
unchanged from baseline during the treatment interruption, but improved after restarting
ART (Childers et al. 2008). Our finding is consistent, however, with results in a single-arm
treatment interruption study of 167 participants with CD4 cell counts>350 cells/mm3
(Robertson et al. 2010), where mean neurocognitive performance improved after stopping
ART for up to 1.5 years, but remained stable in the same patients following ART
recommencement. The initial improvement after stopping ART in the single-arm study may
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have been due to a practice effect, but the absence of further improvement after starting
ART does not support the hypothesis of a beneficial effect in this population; Robertson et
al. (2010) raised the possibility that ART might be neurotoxic. Nevertheless, suppressing
HIV RNA may benefit neurocognitive function in individuals with lower CD4 levels; our
study participants spent 91 % of their total follow-up time at CD4 cell counts above 350
cells/mm3.
The single strongest predictor for change in QNPZ-5 as well as for each individual test was
the baseline test score; participants with lower baseline scores improved more (Table 3). The
same was observed in a previous study of 124 HIV-infected individuals and 172 HIV-
negative controls (Cysique et al. 2011). Such “regression to the mean” effect is common
when the response is change in an outcome that is also included as baseline factor. Women
had, on average, lower increases in QNPZ-5 scores and GPB and CT1 z scores (Table 3).
Limitations of our study include that we could not compare the intermittent versus
continuous ART strategies as originally planned because the intermittent ART arm in the
parent SMART study was stopped by the DSMB and, consequently, most substudy
participants had switched to continuous ART before the first follow-up assessment at month
6. Also, the study was not powered to investigate the effect of individual drugs or drug
classes. Lastly, neurocognitive function was assessed with only five tests, and z scores were
calculated using US norms; therefore, our estimation of the prevalence of NCI needs to be
interpreted with caution. Our main results refer to changes in z scores, however, and thus are
not affected by the use of US versus local norms.
In our study of HIV-infected individuals with high CD4 cell counts, neurocognitive test
results had improved in both study arms by 6 months. The improvement could not be
explained by ART use or changes in CD4 or plasma HIV RNA levels. This suggests the
presence of a practice effect, consistent with findings from other studies (Cysique et al.
2011; Levine et al. 2004; McCaffrey et al. 2000). Our finding emphasizes the need for a
control group in studies that measure an intervention effect using this type of performance
test battery. Where a control group is not possible for ethical reasons, adjustments for a
potential practice effect are needed.
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Study design, CONSORT flow diagram, and use of antiretroviral treatment (ART)
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a Change in QNPZ-5 and z scores from baseline to month 6, with 1 SE indicated by error
bars. b Change in QNPZ-5 scores within subgroups by ART status, and mean CPE rank of
ART at baseline and month 6. *P≤0.05, increase in z score is statistically significant (for
two-sided t test); **P<0.01; ***P<0.001. Superscript letter a estimated difference 0.05
(P=0.40) after adjustment for change in CD4 and HIV RNA. CPE Rank CNS penetration
rank of ART (Letendre et al. 2010), CT Color Trails tests, FT Finger Tapping test
(nondominant hand), GPB Grooved Pegboard (dominant hand), QNPZ-5 quantitative
neurocognitive performance z score, TG Timed Gait test
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Table 1
Baseline characteristics (N=258)
Characteristic Percent or median (IQR)
Demographics
 Age (years) 40 (35, 45)




 White, other, or unknown 24.8
Education (years) 12 (10, 15)
Location of enrollment (%)
 Australia 5.0
 Brazil 6.6
 North America 32.9
 Thailand 55.4
HIV transmission modes (%)
 Male–male sexual 32.2
 Heterosexual 66.7
 Intravenous drug use 3.1
 Other or unknown 8.9
HIV-related factors
 Duration of HIV infection (years) 5 (4, 8)
 Prior AIDS diagnosis (%) 19.0
 CD4 count (cells/mm3) 513 (430, 667)
 Nadir CD4 count (cells/mm3) 216 (161, 290)
 HIV RNA≤400 copies/mL (%) 87.5
Preexisting conditions
 Prior CVDa (%) 3.9
 Baseline ECG; major abnormalityb (%) 11.3
 Diabetes (%) 3.5
 Hepatitis B (%) 2.3
 Hepatitis C (%) 7.0
ART use at baseline
 ART naive (%) 3.9
 Duration of prior ART use (years) 4 (3, 6)




 CPE rankc 7 (7, 8)
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ART antiretroviral therapy, CPE central nervous system penetration effectiveness of ART, CVD cardiovascular disease, PI protease inhibitor,
NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor
a
Previous myocardial infarction (four), stroke (zero), coronary heart disease (three), congestive heart failure (two), or peripheral vascular disease
(five)
b
Major ischaemic abnormalities, atrioventricular blocks, bundle branch blocks, arrhythmias, or left ventricular hypertrophy
c
CNS penetration effectiveness rank of the ART regimen; each drug is scored as 1–4, with higher scores for higher CNS penetration (Letendre et
al. 2010)
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Table 2
Neurocognitive tests, baseline and change to month 6
Baseline Change to month 6
Mean ±1 SD Mean SE P value
QNPZ-5 −0.68* ±0.78 0.17 0.05 <0.001
Test z scoresa
 GPB −0.26* ±1.20 0.25 0.09 <0.001
 CT1 −0.52* ±1.24 0.28 0.10 <0.001
 CT2 −0.00 ±0.99 0.18 0.07 <0.001
 TG −1.64* ±1.75 0.11 0.10 0.15
 FT −0.98* ±1.10 0.03 0.09 0.68
Raw tests scores
 GPB (s) 72.5 ±26.3 −3.8 1.5 <0.001
 CT1 (s) 47.5 ±19.0 −3.8 1.3 <0.001
 CT2 (s) 93.3 ±32.6 −5.1 2.0 <0.001
 TG (s) 11.9 ±2.1 −0.1 0.1 0.19
 FT (taps) 39.3 ±7.9 0.1 0.6 0.90
The QNPZ-5 score, individual test z scores, and raw test scores at baseline, and their change to month 6 are shown for 258 participants, pooled
across the intermittent ART and continuous ART treatment groups. At baseline, the mean QNPZ-5 score and mean z scores for four of the five tests
were below 0, denoting below-average performance compared with a healthy reference population. The QNPZ-5 score and individual test z scores
increased from baseline to month 6; see also Fig. 1. There was no evidence for a treatment difference in mean change in QNPZ-5 or any of the z
scores
CT Color Trails test, FT Finger Tapping test (nondominant hand), GPB Grooved Pegboard test (dominant hand), QNPZ-5 quantitative
neurocognitive performance z score, TG Timed Gait test
*
P<0.001, mean z scores<0 (two-sided t test)
a
z scores were calculated with reference distributions (matched for education [all tests], age [GPB, CT, and FT], gender [GPB and FT], and race/
ethnicity [GPB and FT]). Thirty-five participants (13.6 %) had NCI at baseline, defined as z scores<−2 in at least two cognitive ability domains,
and the same number had NCI at month 6. Of those who were impaired at baseline, 16 participants (46 %) were not impaired at month 6, and vice
versa
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Table 3
Factors associated with change in test z scores from baseline to month 6 in multiple regression models, in 258
participants
Factora QNPZ-5 Regression coefficients for individual test z scores
Coefficient (SE) P value GPB CT1 CT2 FT TG
Baseline z scoreb −0.23*** (0.04) <0.001 −0.36*** −0.48*** −0.32*** −0.49*** −0.26***
Age (years) n.s. n.s. n.s. −0.01* n.s. n.s.
Sex (female) −0.14* (0.07) 0.05 −0.28* −0.27* n.s. n.s. n.s.
Location
 Australia/North America Ref.
 Brazil 0.25 (0.13) 0.06 0.55* n.s. n.s. 0.66** 0.59*
 Thailand 0.15* (0.07) 0.03 0.39** n.s. n.s. n.s. 0.27
Change in CD4 (per 50 cells/mm3 higher) n.s. n.s. n.s. n.s. 0.04* n.s.
Change in log HIV RNA (per 1 log10
copies/mL higher) 0.15
*** (0.06) 0.001 0.19* n.s. n.s. n.s. n.s.
Coefficients were provided when P values for associations were 0.10 or less. Analyses by treatment group: Within the intermittent ART group, an
increase in CD4 was associated with an increase in QNPZ-5 (by 0.03 per 50 cells/mm3 increase; P=0.05), but not with any of the individual tests,
and there was no evidence for an association within the continuous ART group. Associations of an increase in log10 HIV RNAwith increased
QNPZ-5 were similar across both treatment groups. Sensitivity analyses: (1) In a model that included baseline factors only, associations were
similar. (2) Among the 202 participants with HIV RNA≤400 copies/mL at baseline and at month 6, change in CD4 was associated with FT only,
with a similar coefficient
CT Color Trails test, FT Finger Tapping test (nondominant hand), GPB Grooved Pegboard test (dominant hand), QNPZ-5 quantitative






P≤0.001, association is significant in multiple regression (for individual tests)
a
Education (in years) was included as explanatory factor in all regression models, but associations were not significant
b
QNPZ-5 or individual test z score
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